Nuvectis Pharma Initiates NXP900 and Osimertinib Combination Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Nuvectis Pharma announced the initiation of the Phase 1b study of NXP900 in combination with osimertinib in patients with EGFRmut+ NSCLC. NXP900, an oral small molecule drug candidate, is a potent inhibitor of the SRC and YES1kinases. The brand name for Osimertinib is Tagrisso, marketed by Astra Zeneca. Tagrisso, a 3rd generation EGFR inhibitor is broadly used in patients with NSCLCmut+ as single agent or in combination with chemotherapy as a first or later line of therapy. It has been described in the scientific literature that activation of the SRC/YES1 pathway drives resistance to EGFR inhibitor therapy in EGFRmut+ NSCLC. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis commented, "We are pleased to announce the initiation of the NXP900 plus osimertinib combination study, as we continue to advance the NXP900 clinical program and unlock NXP900's promising therapeutic potential." Mr. Bentsur added, "The clinical benefit and improved outcomes afforded by osimertinib to patients with EGFRmut+ NSCLC are well known, and we believe, based on extensive medical and scientific literature and proof of concept experiments done by us and others, that a combination with NXP900 has the potential to extend these benefits in patients who acquired resistance to osimertinib, using an all oral combination of osimertinib and NXP900."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCT
Wall Street analysts forecast NVCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.190
Low
10.00
Averages
15.67
High
20.00
Current: 10.190
Low
10.00
Averages
15.67
High
20.00
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuvectis Pharma to Present at BioConnect Investor Conference
- Investor Conference Participation: Nuvectis Pharma will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its innovative drug development in oncology, which is expected to attract investor interest and enhance the company's visibility.
- Management Presentation: CEO Ron Bentsur will deliver a 30-minute presentation at the conference, detailing the clinical progress of NXP900, aiming to bolster investor confidence through an in-depth explanation of its unique mechanism of action.
- NXP900 Development Progress: NXP900 is an oral small molecule inhibitor targeting SRC family kinases, having completed a Phase 1a dose escalation study and currently undergoing the Phase 1b program, indicating promising clinical prospects.
- Webcast Availability: The presentation will be available via webcast on Nuvectis' investor section of its website, ensuring that investors unable to attend in person can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
See More
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
- Clinical Progress Update: Nuvectis Pharma's NXP900 Phase 1b clinical program continues to enroll patients at top sites in the US, indicating steady advancement in the development of innovative oncology treatments, with preliminary data expected in summer that could positively impact future clinical trials and market positioning.
- Financial Overview: As of March 31, 2026, the company reported cash and cash equivalents of $25.1 million, down from $31.6 million as of December 31, 2025, reflecting the company's funding utilization in R&D and operations, which may influence future fundraising strategies.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $4.1 million, up from $3.7 million in Q1 2025, primarily driven by rising manufacturing costs and employee compensation, a trend that could affect the company's financial health and investor confidence.
- Widening Net Loss: The company reported a net loss of $6.1 million for Q1 2026, compared to a loss of $5.3 million in Q1 2025, highlighting ongoing challenges in profitability despite continued investment in clinical development, which may negatively impact shareholder return expectations.
See More
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
Financial Performance: Nuvectis Pharma, Inc. reported its financial results for the first quarter of 2026, highlighting key metrics and performance indicators.
Business Highlights: The report includes significant business developments and achievements that occurred during the quarter, showcasing the company's progress and strategic initiatives.
See More
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
- Financial Performance: Nuvectis Pharma reported a FY GAAP EPS of -$1.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $31.6 million, an increase of $13.1 million from $18.5 million on December 31, 2024, reflecting some progress in financing.
- Funding Sources: The cash increase was primarily driven by the February 2025 public offering and access to the at-the-market facility, although rising operating expenses have partially offset this growth.
- Market Reaction: Despite the improvement in cash position, ongoing losses may negatively impact the stock price, prompting investors to closely monitor future profitability and cash flow management.
See More
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
- Financial Overview: As of December 31, 2025, Nuvectis reported cash and cash equivalents of $31.6 million, up from $18.5 million in 2024, primarily due to a public offering in February 2025, despite rising operating expenses.
- Increased Net Loss: The company's net loss for 2025 was $26.4 million, an increase of $7.4 million from $19.0 million in 2024, reflecting higher R&D and administrative costs, including $6.0 million in non-cash stock-based compensation and $2.4 million in one-time license fees.
- R&D Spending Growth: Research and development expenses reached $18.2 million in 2025, up from $12.9 million in 2024, indicating the company's ongoing investment in the NXP900 program aimed at advancing its clinical trials.
- Positive Future Outlook: Nuvectis anticipates 2026 to be a pivotal year with multiple clinical data readouts for NXP900 expected, as the company remains focused on operational execution and financial responsibility to support future milestones.
See More
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
- Clinical Study Initiation: Nuvectis Pharma has announced the initiation of a Phase 1b clinical study of NXP900 in combination with osimertinib, targeting patients with EGFR-mutant non-small cell lung cancer (NSCLC), marking a significant advancement in the company's precision oncology efforts.
- Drug Mechanism: NXP900 is an oral small molecule that effectively inhibits SRC and YES1 kinases, addressing resistance mechanisms in EGFR-mutant patients, which could provide new therapeutic options and enhance clinical efficacy.
- Patient Selection Criteria: The study focuses on patients with unresectable metastatic or locally advanced EGFR-mutant NSCLC who have previously responded to osimertinib, ensuring the relevance and potential effectiveness of the study results, which may provide critical data for future treatment strategies.
- Future Outlook: Nuvectis anticipates that 2026 will be a pivotal year with multiple data readouts from both monotherapy and combination studies, further advancing the clinical development of NXP900 and strengthening the company's competitive position in the oncology market.
See More
Nuvectis Pharma to Present at BioConnect Investor Conference
- Investor Conference Participation: Nuvectis Pharma will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its innovative drug development in oncology, which is expected to attract investor interest and enhance the company's visibility.
- Management Presentation: CEO Ron Bentsur will deliver a 30-minute presentation at the conference, detailing the clinical progress of NXP900, aiming to bolster investor confidence through an in-depth explanation of its unique mechanism of action.
- NXP900 Development Progress: NXP900 is an oral small molecule inhibitor targeting SRC family kinases, having completed a Phase 1a dose escalation study and currently undergoing the Phase 1b program, indicating promising clinical prospects.
- Webcast Availability: The presentation will be available via webcast on Nuvectis' investor section of its website, ensuring that investors unable to attend in person can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
See More
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
- Clinical Progress Update: Nuvectis Pharma's NXP900 Phase 1b clinical program continues to enroll patients at top sites in the US, indicating steady advancement in the development of innovative oncology treatments, with preliminary data expected in summer that could positively impact future clinical trials and market positioning.
- Financial Overview: As of March 31, 2026, the company reported cash and cash equivalents of $25.1 million, down from $31.6 million as of December 31, 2025, reflecting the company's funding utilization in R&D and operations, which may influence future fundraising strategies.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $4.1 million, up from $3.7 million in Q1 2025, primarily driven by rising manufacturing costs and employee compensation, a trend that could affect the company's financial health and investor confidence.
- Widening Net Loss: The company reported a net loss of $6.1 million for Q1 2026, compared to a loss of $5.3 million in Q1 2025, highlighting ongoing challenges in profitability despite continued investment in clinical development, which may negatively impact shareholder return expectations.
See More
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
Financial Performance: Nuvectis Pharma, Inc. reported its financial results for the first quarter of 2026, highlighting key metrics and performance indicators.
Business Highlights: The report includes significant business developments and achievements that occurred during the quarter, showcasing the company's progress and strategic initiatives.
See More
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
- Financial Performance: Nuvectis Pharma reported a FY GAAP EPS of -$1.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $31.6 million, an increase of $13.1 million from $18.5 million on December 31, 2024, reflecting some progress in financing.
- Funding Sources: The cash increase was primarily driven by the February 2025 public offering and access to the at-the-market facility, although rising operating expenses have partially offset this growth.
- Market Reaction: Despite the improvement in cash position, ongoing losses may negatively impact the stock price, prompting investors to closely monitor future profitability and cash flow management.
See More
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
- Financial Overview: As of December 31, 2025, Nuvectis reported cash and cash equivalents of $31.6 million, up from $18.5 million in 2024, primarily due to a public offering in February 2025, despite rising operating expenses.
- Increased Net Loss: The company's net loss for 2025 was $26.4 million, an increase of $7.4 million from $19.0 million in 2024, reflecting higher R&D and administrative costs, including $6.0 million in non-cash stock-based compensation and $2.4 million in one-time license fees.
- R&D Spending Growth: Research and development expenses reached $18.2 million in 2025, up from $12.9 million in 2024, indicating the company's ongoing investment in the NXP900 program aimed at advancing its clinical trials.
- Positive Future Outlook: Nuvectis anticipates 2026 to be a pivotal year with multiple clinical data readouts for NXP900 expected, as the company remains focused on operational execution and financial responsibility to support future milestones.
See More
Nuvectis Initiates Phase 1b Study of NXP900 with Osimertinib for EGFRmut+NSCLC
- Clinical Study Initiation: Nuvectis Pharma has announced the initiation of a Phase 1b clinical study of NXP900 in combination with osimertinib, targeting patients with EGFR-mutant non-small cell lung cancer (NSCLC), marking a significant advancement in the company's precision oncology efforts.
- Drug Mechanism: NXP900 is an oral small molecule that effectively inhibits SRC and YES1 kinases, addressing resistance mechanisms in EGFR-mutant patients, which could provide new therapeutic options and enhance clinical efficacy.
- Patient Selection Criteria: The study focuses on patients with unresectable metastatic or locally advanced EGFR-mutant NSCLC who have previously responded to osimertinib, ensuring the relevance and potential effectiveness of the study results, which may provide critical data for future treatment strategies.
- Future Outlook: Nuvectis anticipates that 2026 will be a pivotal year with multiple data readouts from both monotherapy and combination studies, further advancing the clinical development of NXP900 and strengthening the company's competitive position in the oncology market.
See More
